(Q61899519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

meta-analysis

0 references

title

Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Diana Giannarelli

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Michele Milella

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Alain Gelibter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Federica Cuppone

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Maria Simona Pino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Enzo Maria Ruggeri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Paolo Carlini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Cecilia Nisticò

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Edmondo Terzoli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Francesco Cognetti

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

number of pages

9

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

525-533

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Confidence intervals for the number needed to treat

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Development of farnesyl transferase inhibitors: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Gemcitabine doublets in advanced pancreatic cancer: should we move on?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22809

7 January 2021

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002093.PUB2

Identifiers

DOI

10.1002/CNCR.22809

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17577216%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference